Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4361 Target Snapshot

Induced myeloid leukemia cell differentiation protein Mcl-1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
4,508Compounds
425Assays
9Approved Drugs
5,903.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Induced myeloid leukemia cell differentiation protein Mcl-1 shows late clinical disease relevance led by small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q07820. Start with small cell lung carcinoma, then reuse UniProt Q07820 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with small cell lung carcinoma, then reuse UniProt Q07820 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
small cell lung carcinoma

Induced myeloid leukemia cell differentiation protein Mcl-1 shows late clinical disease relevance led by small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with small cell lung carcinoma because it currently carries late clinical support. Linked drugs include OBATOCLAX MESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Induced myeloid leukemia cell differentiation protein Mcl-1 as ChEMBL target CHEMBL4361, mapped to UniProt Q07820. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Induced myeloid leukemia cell differentiation protein Mcl-1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4361
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q07820
Induced myeloid leukemia cell differentiation protein Mcl-1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Induced myeloid leukemia cell differentiation protein Mcl-1 is the right protein anchor across sources, using UniProt Q07820 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why small cell lung carcinoma is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameInduced myeloid leukemia cell differentiation protein Mcl-1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ07820
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelInduced myeloid leukemia cell differentiation protein Mcl-1
UniProt AccessionQ07820
Component TypeProtein
Sequence Length350 aa

Induced myeloid leukemia cell differentiation protein Mcl-1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Induced myeloid leukemia cell differentiation protein Mcl-1, mapped to UniProt Q07820. Sequence length is 350 aa.

Mapped IDQ07820
Review nameInduced myeloid leukemia cell differentiation protein Mcl-1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Induced myeloid leukemia cell differentiation protein Mcl-1 shows late clinical disease relevance led by small cell lung carcinoma. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
small cell lung carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugOBATOCLAX MESYLATE
Clinical signal Phase II
follicular lymphoma
1 linked drug · 1 direct · 1 efficacy
Linked drugOBATOCLAX MESYLATE
Clinical signal Phase II
Hodgkins lymphoma
1 linked drug · 1 direct · 1 efficacy
Linked drugOBATOCLAX MESYLATE
Clinical signal Phase II
myelodysplastic syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugOBATOCLAX MESYLATE
Clinical signal Phase II
myelofibrosis
1 linked drug · 1 direct · 1 efficacy
Linked drugOBATOCLAX MESYLATE
Clinical signal Phase I
chronic lymphocytic leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugOBATOCLAX MESYLATE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with small cell lung carcinoma because it currently carries late clinical support. Linked drugs include OBATOCLAX MESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasesmall cell lung carcinoma
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

9
Approved
8
Phase III
1
Phase II
7
Phase I
Assay Mix

Activity Type Distribution

IC502,474.0
KI3,277.0
EC5019.0
KD133.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5768839 10.96 Ki 0.011 Preclinical
CHEMBL5799571 10.96 Ki 0.011 Preclinical
CHEMBL4650225 10.92 Ki 0.012 Preclinical
CHEMBL5775900 10.92 Ki 0.012 Preclinical
CHEMBL5902520 10.89 Ki 0.013 Preclinical
CHEMBL5396628 10.89 Ki 0.013 Preclinical
CHEMBL5809179 10.89 Ki 0.013 Preclinical
CHEMBL5181717 10.85 Ki 0.014 Preclinical
CHEMBL5845523 10.85 Ki 0.014 Preclinical
CHEMBL5307201 10.82 Ki 0.015 Preclinical
Distribution

pChEMBL Value Distribution

959
5.0
701
5.5
517
6.0
464
6.5
277
7.0
130
7.5
180
8.0
271
8.5
143
9.0
97
9.5
pChEMBL
Assay Landscape

Assay Landscape

425
Total Assays
2,631
Tested Compounds
2
Assay Types
Binding — 419 assays, 2,631 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 240 1,735 7.1
cell-based format 94 237 5.4
assay format 84 659 6.3
subcellular format 1 0 —
Functional — 6 assays, 992 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 5 0 —
assay format 1 992 5.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine